Pieris Pharmaceuticals, Inc.

  • Home
  • About
  • Platform
  • Pipeline
  • Patients
  • Investors
    • Overview
    • News & Events
    • Publications
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
    • Job Openings
  • Contact
  • News & Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts
Jan 10, 2023 8:00am EST

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)

Nov 23, 2022 8:00am EST

Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference

Nov 09, 2022 8:00am EST

Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference

Nov 02, 2022 7:00am EDT

Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 01, 2022 9:15am EDT

Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

Oct 26, 2022 8:00am EDT

Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022

Sep 08, 2022 4:01pm EDT

Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 24, 2022 8:00am EDT

Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS

Aug 04, 2022 7:00am EDT

Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 28, 2022 7:20am EDT

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …25
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2023 Pieris Pharmaceuticals, Inc. All Rights Reserved.
Imprint Privacy Policy Disclaimer Sitemap Contact Us Manage Cookie Preferences